{"prompt": "['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '13.', 'IMPORTANT MEDICAL PROCEDURES TO BE FOLLOWED', 'BY THE INVESTIGATOR', '13.1', 'Overdose', 'There is currently no specific treatment in the event of overdose with olaparib and possible', 'symptoms of overdose are not established.', 'Olaparib must only be used in accordance with the dosing recommendations in this protocol.', 'Any dose or frequency of dosing that exceeds the dosing regimen specified in this protocol', 'should be reported as an overdose. The Maximum Tolerated Dose is 300 mg bid (tablet).', 'Adverse reactions associated with overdose should be treated symptomatically and should be', 'managed appropriately.', 'An overdose with associated AEs is recorded as the AE diagnosis/symptom: on the', 'relevant AE modules in the eCRF and on the Overdose CRF module.', 'An overdose without associated symptoms is only reported on the Overdose CRF module.', 'If an overdose on an AstraZeneca study drug occurs in the course of the study, then', 'investigators or other site personnel inform appropriate AstraZeneca representatives within', 'one day, i.e., immediately but no later than the end of the next business day of when he or', 'she becomes aware of it.', 'The designated AstraZeneca representative works with the investigator to ensure that all', 'relevant information is provided to the AstraZeneca Patient Safety data entry site.', 'For overdoses associated with SAE, standard reporting timelines apply, see Section 6.2.7. For', 'other overdoses, reporting should be done within 30 days.', '13.1.1', 'Paternal exposure', 'Male patients should refrain from fathering a child or donating sperm during the study and for', '3 months following the last dose.', \"Pregnancy of the patient's partners is not considered to be an adverse event. However, the\", 'outcome of all pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy,', 'normal birth or congenital abnormality) should if possible be followed up and documented.', 'The outcome of any conception occurring from the date of the first dose until 3 months after', 'the last dose should be followed up and documented.', '77(93)', 'Printed on 3/25/202']['IRB Approved', '9984', 'Document Release Date: 03/25/2021', 'Clinical Study Protocol', 'Drug Substance Olaparib (AZD2281, KU-0059436); Testosterone', 'Consortium Study Number 9984', 'Edition Number 1.6', 'Date February 24, 2021', '14.', 'LIST OF REFERENCES', '1.', 'Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of', 'estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the', 'prostate. Cancer Res 1941; 1: 293-297.', '2.', 'Brendler H, Chase WE, Scott WW. Prostatic cancer; further investigation of hormonal', 'relationships. Arch Surg 1950; 61: 433-440.', '3.', 'Prout GR, Jr., Brewer WR. Response of men with advanced prostatic carcinoma to', 'exogenous administration of testosterone. Cancer 1967; 20: 1871-1878.', '4.', 'Fowler JE, Jr., Whitmore WF, Jr. The response of metastatic adenocarcinoma of the', 'prostate to exogenous testosterone. J Urol 1981; 126: 372-375.', '5.', 'Leibowitz RL, Dorff TB, Tucker S et al. Testosterone replacement in prostate cancer', 'survivors with hypogonadal symptoms. BJU Int 2010; 105: 1397-1401.', '6.', 'Denmeade SR, Isaacs JT. Bipolar androgen therapy: the rationale for rapid cycling of', 'supraphysiologic androgen/ablation in men with castration resistant prostate cancer. Prostate', '2010; 70: 1600-1607.', '7.', \"Isaacs JT, D'Antonio JM, Chen S et al. Adaptive auto-regulation of androgen receptor\", 'provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate', 'resistant human prostate cancer. Prostate 2012.', '8.', 'Litvinov IV, Vander Griend DJ, Antony L et al. Androgen receptor as a licensing', 'factor for DNA replication in androgen-sensitive prostate cancer cells. Proc Natl Acad Sci U S', 'A 2006; 103: 15085-15090.', '9.', 'Vander Griend DJ, Litvinov IV, Isaacs JT. Stabilizing androgen receptor in mitosis', 'inhibits prostate cancer proliferation. Cell Cycle 2007; 6: 647-651.', '10.', 'Haffner MC, Aryee MJ, Toubaji A et al. Androgen-induced TOP2B-mediated double-', 'strand breaks and prostate cancer gene rearrangements. Nat Genet 2010; 42: 668-675.', '11.', 'Schweizer MT, Antonarakis ES, Wang H et al. Effect of bipolar androgen therapy for', 'asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.', 'Sci Transl Med 2015; 7: 269ra262.', '12.', 'Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016; 66: 7-', '30.', '13.', 'Beer TM, Armstrong AJ, Rathkopf DE et al. Enzalutamide in Metastatic Prostate', 'Cancer before Chemotherapy. N Engl J Med 2014.', '14.', 'de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in', 'metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.', '15.', 'de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or', 'mitoxantrone for metastatic castration-resistan prostate cancer progressing after docetaxel', 'treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154.', '16. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-', 'resistant prostate cancer. N Engl J Med 2010; 363: 411-422.', '17.', 'Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in', 'metastatic prostate cancer. N Engl J Med 2013; 369: 213-223.', '18.', 'Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared', 'with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med', '2004; 351: 1513-1520.', '78(93)', 'Printed on 3/25/202']\n\n###\n\n", "completion": "END"}